Related Experiment Videos
Somatostatin receptors in malignant tissues.
J C Reubi1, E Krenning, S W Lamberts
1Sandoz Research Institute, Berne, Switzerland.
The Journal of Steroid Biochemistry and Molecular Biology
|December 20, 1990
Summary
High affinity somatostatin receptors (SS-R) are present in many human tumors, including pituitary, brain, and breast cancers. These SS-R+ tumors may respond to somatostatin analogs for therapeutic and diagnostic applications.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- High-affinity somatostatin receptors (SS-R) are expressed in various human tissues.
- Understanding SS-R expression in tumors is crucial for targeted therapies.
Purpose of the Study:
- To investigate the presence and distribution of SS-R in a wide range of human tumors.
- To explore the functional implications of SS-R in tumor growth and hormone secretion.
Main Methods:
- Analysis of SS-R expression in human tumor samples using membrane homogenates and tissue sections.
- Autoradiography for assessing SS-R distribution in specific tumor types.
- In vivo imaging techniques using radiolabeled SS analogs.
Main Results:
- SS-R were identified in numerous human tumors, including pituitary, gastroenteropancreatic (GEP), brain, breast, lung, colorectal, and thyroid carcinomas.
- SS-R expression was often associated with well-differentiated tumors, neuroendocrine features, and low epidermal growth factor receptor (EGF-R) expression.
- SS-R mediate hormone secretion inhibition and antiproliferative effects in preclinical models, suggesting therapeutic potential.
Conclusions:
- High-affinity SS-R are widely expressed in human tumors, offering potential targets for diagnosis and therapy.
- SS-R status in tumors can be assessed using autoradiography and in vivo imaging.
- Somatostatin analogs show promise in inhibiting the growth of SS-R-expressing tumors.